Reemergence of PML in Natalizumab-Treated Patients - New Cases, Same Concerns

被引：68
作者：
Major, Eugene O. [1 ]
机构：
[1] NINDS, Lab Mol Med & Neurosci, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2009年 / 361卷 / 11期
关键词：
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANTIBODY NATALIZUMAB; CELLS;
D O I：
10.1056/NEJMp0906248
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1041 / 1043
页数：3
相关论文
共 41 条
  • [31] Biogen Idec and Elan have announced four new cases of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri (natalizumab),
    [J]. Reactions Weekly, 2010, 1290 (1) : 3 - 3
  • [32] Three cases of herpes zoster radiculitis in MS patients treated with natalizumab
    Yamout, Bassem I.
    Abou Zeid, Nuhad
    Taha, Ali J.
    Zeineddine, Maya M.
    Khoury, Samia J.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 9 : 122 - 124
  • [33] Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis
    Kohlmann, Rebekka
    Salmen, Anke
    Chan, Andrew
    Knabbe, Cornelius
    Diekmann, Juergen
    Brockmeyer, Norbert
    Skaletz-Rorowski, Adriane
    Michalik, Claudia
    Gold, Ralf
    Ueberla, Klaus
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (14) : 1823 - 1832
  • [34] Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients
    Achiron, Anat
    Miron, Gadi
    Zilkha-Falb, Rina
    Magalashvili, David
    Dolev, Mark
    Stern, Yael
    Gurevich, Michael
    [J]. JOURNAL OF NEUROVIROLOGY, 2016, 22 (06) : 736 - 746
  • [35] Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients
    Basnyat, Pabitra
    Hagman, Sanna
    Kolasa, Marcin
    Koivisto, Keijo
    Verkkoniemi-Ahola, Auli
    Airas, Laura
    Elovaara, Irina
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2015, 4 (04) : 334 - 338
  • [36] JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level
    Lanzillo, Roberta
    Liuzzi, Raffaele
    Vallefuoco, Luca
    Moccia, Marcello
    Amato, Luca
    Vacca, Giovanni
    Vacchiano, Veria
    Portella, Giuseppe
    Morra, Vincenzo Brescia
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 807 - 814
  • [37] JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients
    Basnyat, Pabitra
    Virtanen, Elina
    Elovaara, Irina
    Hagman, Sanna
    Auvinen, Eeva
    [J]. JOURNAL OF NEUROVIROLOGY, 2017, 23 (05) : 734 - 741
  • [38] A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort
    Outteryck, O.
    Ongagna, J. C.
    Brochet, B.
    Rumbach, L.
    Lebrun-Frenay, C.
    Debouverie, M.
    Zephir, H.
    Ouallet, J. C.
    Berger, E.
    Cohen, M.
    Pittion, S.
    Laplaud, D.
    Wiertlewski, S.
    Cabre, P.
    Pelletier, J.
    Rico, A.
    Defer, G.
    Derache, N.
    Camu, W.
    Thouvenot, E.
    Moreau, T.
    Fromont, A.
    Tourbah, A.
    Labauge, P.
    Castelnovo, G.
    Clavelou, P.
    Casez, O.
    Hautecoeur, P.
    Papeix, C.
    Lubetzki, C.
    Fontaine, B.
    Couturier, N.
    Bohossian, N.
    Clanet, M.
    Vermersch, P.
    de Seze, J.
    Brassat, D.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (01) : 40 - 48
  • [39] Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study
    Santiago-Setien, Pilar
    Barquin-Rego, Cristina
    Hernandez-Martinez, Paula
    Ezquerra-Marigomez, Maria
    Torres-Barquin, Marta
    Menendez-Garcia, Cristina
    Uriarte, Fernando
    Jimenez-Lopez, Yesica
    Misiego, Mercedes
    de la Torre, Jose Ramon Sanchez
    Setien, Sonia
    Delgado-Alvarado, Manuel
    Riancho, Javier
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [40] Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy
    Piu, Claudia
    Ibba, Gabriele
    Bertoli, Diego
    Capra, Ruggero
    Uleri, Elena
    Serra, Caterina
    Imberti, Luisa
    Dolei, Antonina
    [J]. JOURNAL OF NEUROVIROLOGY, 2020, 26 (01) : 133 - 137
12345